Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Healthcare Medical Devices

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.

TSXV:THRM - Post by User

Therma Bright Inc > News

<< Previous

Bullboard Posts

Next >>

Comment by hemi3tcon Mar 18, 2021 1:43pm

198 Views

Post# 32827195

RE:RE:RE:RE:News

The test only works on high viral loads. So test results that were low to mid viral loads that tested negative were excluded.

Whydunnit wrote:
forrest6748 wrote: Interesting number changes. Major upgrade

Mr. Fia went on to say, "Recent lab results of our locked test showed 100% sensitivity and 100% specificity in most patients when tested within 7 days of onset of symptoms. This is the test that will be entering the performance study."

Those are great numbers but the thing that bothers me is what does "most patients" mean? If something is going to be 100% shouldn't it include all patients? Did they exclude 10% of patients for whom it wasn't 100%? That would make it sort of 100% but not really. Also, it says they are lab results. Shouldn't it say field results if patients were involved? I wish they'd learn how to write their NRs clearly and unambiguously.

Anyway, it's great that they're field testing in Brazil. This would be separate from a HC application and could very well get official approval in Brazil and then the rest of South America, with the data to be used also as corroboration for HC, FDA and European applications with their own separate date sets.